NCT02022436View on ClinicalTrials.gov

Evaluation of Predictors of Aortic Aneurysm Growth and Rupture

PHASE2CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

February 28, 2022

Study Completion Date

February 28, 2022

Conditions
Abdominal Aortic Aneurysm
Interventions
DRUG

Contrast Ultrasound

Definity® is the contrast agent that will be administered by intravenous injection by a registered nurse during the ultrasound (contrast enhanced ultrasound (CUS). The purpose is to assist in identifying differences in AAA characteristics based on gender and AAA stability and growth.

Trial Locations (1)

15232

University of Pittsburgh Medical Center, Division of Vascular Surgery, Pittsburgh

All Listed Sponsors
collaborator

National Institute on Aging (NIA)

NIH

lead

Rabih A. Chaer

OTHER

NCT02022436 - Evaluation of Predictors of Aortic Aneurysm Growth and Rupture | Biotech Hunter | Biotech Hunter